<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608074</url>
  </required_header>
  <id_info>
    <org_study_id>FIMBRIECTOMIE</org_study_id>
    <nct_id>NCT01608074</nct_id>
  </id_info>
  <brief_title>Radical Fimbriectomy for Young BRCA Mutation Carriers</brief_title>
  <acronym>Fimbriectomy</acronym>
  <official_title>Radical Fimbriectomy for Young BRCA Mutation Carriers at Risk of Pelvic Serous Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some BRCA-mutated women are reluctant to undergo laparoscopic bilateral
      salpingo-oophorectomy. The goal of the bilateral laparoscopic radical fimbriectomy the
      investigators suggest, is to suppress the tubal source of possible dysplastic cells from
      which can stem this high grade tumor, while preserving a natural ovarian hormonal secretion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most of ovarian carcinomas related to BRCA 1 or 2 mutations are of fallopian tube origin and
      especially from its distant part called the fimbria. These tubal, ovarian or primary
      peritoneal carcinomas are quite always of high grade serous type. They cannot be effectively
      screened due to the quickness of their evolution. In this context, a laparoscopic bilateral
      salpingo-oophorectomy (BSO) is the recommended prophylactic procedure.

      Some BRCA-mutated women are reluctant to undergo this procedure considering the numerous
      adverse effects on body and quality of life, especially when hormonal replacement is
      forbidden. This refusal makes them at risk of developing a serous pelvic carcinoma.

      The goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to
      suppress the tubal source of possible dysplastic cells from which can stem this high grade
      tumor, while preserving a natural ovarian hormonal secretion
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pelvic cancer</measure>
    <time_frame>an expected average of 15 years</time_frame>
    <description>Number of ovarian or primary serous peritoneal carcinoma occuring between fimbriectomy and menopause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity associated with the radical prophylactic fimbriectomy</measure>
    <time_frame>Up to 30 days after the surgery</time_frame>
    <description>Morbidity will be assessed according to the Clavien-Dindo classification up to 30 days after the procedure and according to the NCI-CTCAE v4.0 grading scale beyond that time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of occult lesions on fimbriectomy specimens</measure>
    <time_frame>Within 1 month after surgery</time_frame>
    <description>Number of serous tubal intraepithelial carcinoma or invasive carcinomas on the operative specimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of breast cancer or recurrence of breast cancer</measure>
    <time_frame>an expected average of 15 years</time_frame>
    <description>Number of cases of breast cancer or breast cancer recurrence observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of secondary oophorectomies and associated morbidity</measure>
    <time_frame>an expected average of 15 years</time_frame>
    <description>Number of oophorectomies and time between fimbriectomy and oophorectomy Complications according to NCI-CTCAE v4.0 grading scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <condition>Hereditary Breast and Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>BRCA mutation carriers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with BRCA1 or BRCA 2 mutation or a family history of breast/ovarian cancer.
Radical fimbriectomy. Histopathology SEE-FIM</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical fimbriectomy</intervention_name>
    <description>Laparoscopic bilateral radical fimbriectomy :
Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)</description>
    <arm_group_label>BRCA mutation carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Histopathology SEE-FIM</intervention_name>
    <description>Anatomopathological study of surgical specimens</description>
    <arm_group_label>BRCA mutation carriers</arm_group_label>
    <other_name>Sectioning and Extensively Examining the FIMbria</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman aged over 35 years

          -  When project of childbearing is fulfilled

          -  With a BRCA 1 or 2 mutation, or a family history of breast/ovarian cancer

          -  Unprepared to undergo bilateral annexectomy

          -  With or without breast cancer

          -  Patient affiliated to health insurance

          -  Dated and signed informed consent

        Exclusion Criteria:

          -  Menopausal woman defined as :

        Bilateral oophorectomy without hysterectomy and amenorrhea more than 12 months and/or FSH&gt;
        20 UI/l History of hysterectomy and FSH&gt; 20 UI/l

          -  Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric LEBLANC, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Polyclinique du Parc Rambot</name>
      <address>
        <city>Aix en Provence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR-U</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Bois - Bourgogne Center</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé VA</name>
      <address>
        <city>Villeneuve-d'Ascq</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRCA1</keyword>
  <keyword>BRCA2</keyword>
  <keyword>Prophylactic surgery</keyword>
  <keyword>Salpingectomy</keyword>
  <keyword>Fimbriectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

